^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hairy Cell Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    11/03/2023
    Excerpt:
    Hairy Cell Leukemia: Useful in Certain Circumstances...Venetoclax ± rituximab...